| Â | Estimate | RSE (%) | IIV | Shrinkage (%) |
|---|
KL (week−1) | 0.00464 | 8.59 | 1.05 | 25.9 |
KDE1 (week−1) | 0.0566 | 3.95 | 0.699 | 18.3 |
λ1 (week−1) | 0.117 | 6.06 | Fixed to 0 |  |
KDE2 (week−1) | 0.00412 | 18.2 | 1.64 | 42.1 |
λ2 (week−1) | 0.0597 | 14.9 | 0.787 | 74.3 |
BASE (cm) | 7.74 | 1.67 | 0.642 | 3.5 |
σ2 (cm2) | 0.58 | 9.14 | - | 28.8 |
-
BASE estimated baseline tumor size, IIV standard deviation of inter-individual variability, KDE and λ drug effect and drug effect decay over time, respectively for first-line treatment run-in phase (KDE1 and λ1) and maintenance treatment phase (KDE2 and λ2), KL growth rate (assumed to be same during the two treatment phases), RSE relative standard error of parameter estimates, TGI tumor growth inhibition, σ standard deviation of residual variability
